The live clocks stayed empty. The morning map largely stands.

The afternoon did not strengthen the morning map. Today's finding is failed propagation: the live clocks — interconnection, Hemerdon offtake, cheap-intercept task orders, hair-loss session readouts — stayed empty. The pattern hair-loss frontier from the morning held on prior primaries but did not propagate.

The afternoon did not strengthen the morning map. Today was failed propagation on the clocks the book was already watching — not a new discovery session.

The morning thesis map largely stands. SLB–Kelvion cooling capital, nVent–Maverick switchgear, government-backed minerals packages, the May cheap-intercept IDIQ, and the new pattern hair-loss frontier all carry forward unchanged. Nothing in today's tape upgraded them.

What changed since the morning

**AI power** — unchanged. Cooling and switchgear M&A remain announced, not closed. The interconnection clock stayed empty after chase: retrieval surfaced commentary and peripheral power pivots, not a utility or developer filing that names data-center load or queue position.

**Critical minerals** — unchanged. Hemerdon offtake is still unsigned. No third government package dated today cleared primary verification.

**Defense / counter-autonomy** — unchanged. No disclosed task orders or quantities under the May cheap-intercept vehicle. Exquisite interceptor frameworks from prior sessions remain the louder procurement print.

**RAS oncology** — unchanged. One labeled use; no second tumor-type readout.

**Healthcare × Consumer — pattern hair loss** — the morning's new frontier held but did not propagate. Chase from company primaries confirms a credible three-name competitive map (Veradermics, Cosmo, Absci), corporate financing on the lead public name, and separate male/female regulatory paths. Consumer expansion — whether treatment normalizes beyond today's generic/minoxidil pool — remains unconfirmed. Session retrieval returned stale secondary clips, not a new clinical or regulatory print.

**Gold / macro** — consensus carry. Commentary on yields and central-bank buying is not a new monetary thesis.

Map

Strengthening lanes unchanged on AI power, critical minerals, and defense. Healthcare and consumer carry the pattern hair-loss Early Bridge from the morning without session reinforcement. Distress and wildcards: no candidate promoted in this hunt cycle.

What should happen next

A named interconnection or transformer-backlog primary. A signed Hemerdon offtake or a minerals package that is actually new. Cheap-intercept IDIQ task orders with quantities. Veradermics Phase 3 Study 304 readout (2H 2026) or Cosmo U.S. filing progress (early 2027 target). Until then, empty clocks remain the finding.

What would invalidate

Kelvion or Maverick deals fail while equipment scarcity eases without explanation. Public minerals packages slip repeatedly; offtakes never sign. Cheap-intercept IDIQ produces no meaningful orders while PAC-3/THAAD remain the only industrial print. Pattern hair loss: Phase 3 misses, safety blocks adoption, or launches that only cannibalize generics without expanding the treated population.